Ropinirole - immediate-release tablets

The immediate-release label separates the hemodialysis regimens: Parkinson disease starts at 0.25 mg three times daily, maximum 18 mg/day; RLS starts at 0.25 mg once daily, maximum 3 mg/day. RLS administration is 1-3 hours before bedtime. Subsequent increases depend on response and tolerability. No postdialysis supplement is required. CrCl 30-50 mL/min needs no adjustment; severe impairment below 30 without regular dialysis remains unstudied. These renal instructions do not establish whether a dopamine agonist is the preferred RLS treatment.

At CrCl 30-50 mL/min, no adjustment is needed. For adults receiving regular hemodialysis, Parkinson disease treatment starts at 0.25 mg three times daily and has a maximum of 18 mg/day. The distinct restless legs syndrome (RLS) regimen starts at 0.25 mg once daily, 1-3 hours before bedtime, with a dialysis maximum of 3 mg/day. Titrate to response and tolerability; no supplemental postdialysis dose is required. Severe impairment below 30 without regular dialysis has not been studied. These are immediate-release, indication-specific instructions, not extended-release dosing.

The AASM guideline abstract conditionally suggests against standard ropinirole use for adult RLS, with moderate-certainty evidence. Conditional recommendations require attention to individual circumstances and preferences; this is not an absolute prohibition. A label can describe dosing when a drug is selected while a guideline questions its routine treatment role. This treatment-selection recommendation does not supply an alternative renal dose or override the separate product/formulation instructions.